Ranibizumab ( 0.3 mg or 0.5 mg ) decreases leakage secondary to macular telangiectasia type 2 , but accompanying improvements in best-corrected visual acuity appear similar to improvements in the untreated fellow eye where retinal thickness is relatively unchanged .